TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO) Following Monlunabant Obesity Update

Monlunabant early obesity data not a key driver for Novo Nordisk (NVO) - BMO

September 20, 2024 9:56 AM EDT

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $160.00 price target on Novo Nordisk (NYSE: NVO) after mixed Monlunabant obesity data.

The analyst commented, "Monlunabant phase 2a: Good weight loss, some psychiatric imbalance, good enough for a phase 2b. Headline number is... More

Novo Nordisk shares fall after Monlunabant phase 2a trial results; Viking jumps

September 20, 2024 9:31 AM EDT

Shares in Novo Nordisk (NYSE: NVO) fell more than 4% following the market open on Friday after the Danish pharma giant released data from a phase 2a clinical trial with its obesity drug, monlunabant.

Meanwhile, Viking Therapeutics (NASDAQ: VKTX), one of Novos rivals in the weight-loss market, saw its shares rise over 1%.

The trial assessed the efficacy and... More

Corbus Pharma (CRBP) sink over 55% on Novo Nordisk (NVO) data

September 20, 2024 9:00 AM EDT

Shares of Corbus Pharma (NASDAQ: CRBP) are trading over 55% lower in pre-market on Friday, after competitor Novo Nordisk (NYSE: NVO) released latest clinical data.

... More

Corbus Pharma (CRBP) Quickly Falls 52%

September 20, 2024 8:54 AM EDT

(Updated - September 20, 2024 9:00 AM EDT)

(Updated - September 20, 2024 8:55 AM EDT)

Corbus Pharma (NASDAQ: CRBP) Quickly Falls 52%

Weakness appears to be tied to results from Novo Nordisk (NYSE: NVO)Corbus Pharma's CRB-913 is a... More

Novo Nordisk (NVO) Declines 2.5% After Headline Results from Phase 2a Clinical trial with Monlunabant

September 20, 2024 8:52 AM EDT

(Updated - September 20, 2024 8:57 AM EDT)

Novo Nordisk (NYSE: NVO) Declines 2.5% After Headline Results from Phase 2a Clinical trial with Monlunabant

Some traders pointed out adverse events that were "dose dependent."

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule... More

Novo Nordisk (NVO): Monlunabant phase 2a trial in obesity successfully completed

September 20, 2024 8:46 AM EDT

(Updated - September 20, 2024 8:49 AM EDT)

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].

The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome1. People were... More